Paricalcitol NDC 25000-017

NDC codes

FDA NDC Directory

Product NDC (as listed)25000-017Labeler and product segments. Claims need a package NDC.

Product NDC at billing width25000-0017Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
25000-017-03	25000001703	30 CAPSULE, LIQUID FILLED in 1 BOTTLE (25000-017-03)Marketed from Dec 31, 2016
25000-017-49	25000001749	4 BAG in 1 BOX (25000-017-49) / 7000 CAPSULE, LIQUID FILLED in 1 BAGMarketed from Dec 31, 2016

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Paricalcitol
Generic name (nonproprietary): paricalcitol
Active ingredients: Paricalcitol — 4 ug/1
Dosage form: Capsule, Liquid filled
Route: Oral
Labeler: MARKSANS PHARMA LIMITED
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 204948
Marketing start: Dec 31, 2016
Listing expires: Dec 31, 2026
Other FDA classes: Cholecalciferol (Chemical structure)
Identifiers: Product ID 25000-017_d2da21f1-d7f6-43c0-b66f-5b7d14774688SPL ID d2da21f1-d7f6-43c0-b66f-5b7d14774688SPL set ID 0fbaff52-f08f-42b7-8e46-c7214112901aRxCUI 577315, 577317, 577324UNII 6702D36OG5
Pharmacologic class: Vitamin D3 Analog

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N425000001703 followed by a unit qualifier and the quantity

Package 25000-0017-03. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective May 26, 2017.

Indications (excerpt from the label)

1.1 Chronic Kidney Disease Stages 3 and 4 Paricalcitol Capsules are indicated in adults for the prevention and treatment of secondary hyperparathyroidism associated with Chronic Kidney Disease (CKD) Stages 3 and 4. Pediatric use information for patients 10 to 16 years of age is approved for AbbVie Inc.’s Zemplar (Paricalcitol) capsules. However, due to AbbVie Inc.’s marketing exclusivity rights, this drug product is not labeled with that pediatric information. 1.2 Chronic Kidney Disease Stage 5 Paricalcitol Capsules are indicated in adults for the prevention and treatment of secondary hyperparathyroidism associated with CKD Stage 5 in patients on hemodialysis (HD) or peritoneal dialysis (PD)…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 204948

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 204948
Product	Strength	Form · route	Labeler	Product NDC
Paricalcitol	Paricalcitol 4 ug/1	Capsule, Liquid filledOral	TIME CAP LABORATORIES, INC	49483-689
Paricalcitol	Paricalcitol 1 ug/1	Capsule, Liquid filledOral	TIME CAP LABORATORIES, INC	49483-687
Paricalcitol	Paricalcitol 2 ug/1	Capsule, Liquid filledOral	TIME CAP LABORATORIES, INC	49483-688
Paricalcitol	Paricalcitol 2 ug/1	Capsule, Liquid filledOral	MARKSANS PHARMA LIMITED	25000-014
Paricalcitol	Paricalcitol 1 ug/1	Capsule, Liquid filledOral	MARKSANS PHARMA LIMITED	25000-012